Patterns of antibiotic use, knowledge, and perceptions among different population categories: A comprehensive study based in Arabic countries

Alsayed, Ahmad R.; Hajji, Feras Darwish El; Al-Najjar, Mohammad A A; Abazid, Husam; Al-Dulaimi, Abdullah

doi:10.1016/j.jsps.2022.01.013

Cited by 18 publications

(17 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the lack of specific effective agents for COVID-19 and continuing usage of antibiotic and antiviral agents increase the possibility of gut microbiota imbalance (dysbiosis) and other negative consequences among COVID-19 patients. 19,20 In this study, the length of hospital stay was 12 days for all patients; 10 days for the survivor patients, and 13 days for the non-survivor patients, which is lower than that reported in a previous study. 8 The mortality rate (22.7%) was lower in this study as compared to other previous studies.…”

Section: Discussioncontrasting

confidence: 60%

Using laboratory parameters as predictors for the severity and mortality of COVID-19 in hospitalized patients

Al-Shajlawi¹,

Alsayed²,

Abazid³

et al. 2022

PHARMPRACT

Self Cite

View full text Add to dashboard Cite

Objective:The aim of this study was to explore association of initial laboratory parameters of hospitalized patients with COVID-19, with the severity and death incident. Methods: In this retrospective study, patients were classified based on mortality outcome (survivor and non-survivor) and disease severity (non-severe, severe, and critical). The initial laboratory data (within the first two days of hospital admission) were compared between these categories. Results: Of 362 COVID-19 patients hospitalized between January-2021 and May-2021, 39.0% were non-severe, 32.2% severe, and 28.7% critical. 77.3% were lived and 22.7% died in hospital. Non-survivors were significantly older than survivors. There was a statistically significant association between exceeding the cut-points of laboratory parameters and the severity of the disease or even death. These laboratory parameters included D-dimer, C-reactive protein, prothrombin time, ferritin, white blood cells, neutrophil count, aspartate aminotransferase, creatinine, blood urea nitrogen, lymphocyte count, and albumin. Also, exceeding the cut-points of these parameters showed high odds of death. The highest odds ratio was reported for albumin <3.5 g/ dL (OR=14. 318 [4.784-42.851], p<0.001). Conclusion: The cut-points of the laboratory parameters could effectively be used as predictors to assess the severity and risk of death to improve the management of COVID-19 patients.

show abstract

Section: Discussioncontrasting

confidence: 60%

Using laboratory parameters as predictors for the severity and mortality of COVID-19 in hospitalized patients

Al-Shajlawi¹,

Alsayed²,

Abazid³

et al. 2022

PHARMPRACT

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinicians often administer antibiotics to people who have asthma exacerbations ‘simply to be safe,’ and this practice should be avoided. 48 , 49 While fever may aid in the differentiation of these two illnesses in young and elderly populations, caution should be maintained because fever may be present in other virus-induced asthma exacerbations. Additionally, headache, myalgia, pharyngitis, runny nose, loss of smell and taste, nausea, vomiting, and diarrhoea may help differentiate COVID-19 from asthma.…”

Section: Discussionmentioning

confidence: 99%

Investigating the human rhinovirus co-infection in patients with asthma exacerbations and COVID-19

et al. 2022

Self Cite

View full text Add to dashboard Cite

Objective: To investigate the co-infections with human rhinovirus (HRV) among patients with asthma exacerbation and COVID-19 in Jordan. Also, to determine the frequency of acute asthma exacerbation before and during the COVID-19 pandemic on a matched basis. Methods: The data of this prospective cohort research consisted of clinical variables. During the first visit, and after 14-days, nasopharyngeal swabs were taken and the quantitative polymerase chain reaction was performed for HRV and SARS-CoV-2 detection. Results: Forty-seven out of 175 (26.9%) COVID-19 adult cases have been diagnosed with asthma. The number of asthma exacerbations among the study participants was higher during 2021 than in 2020 (p=0.035). Most of the included asthmatic participants (61.7%) were only positive for SARS-CoV-2 and 38.3% were co-infected with HRV. The SARS-CoV-2 cycle threshold value was lower in samples infected with both viruses compared to samples infected with SARS-CoV-2 alone, p<0.005. Conclusion: Our findings indicate that HRV and SARS-CoV-2 were significantly more prevalent in asthma exacerbations than stable asthma. Thus, HRV and/or SARS-CoV-2 infections were potentially cofactors or contributors to the asthma exacerbation in this cohort. This is the first study, in Jordan, to investigate the HRV co-infection in COVID-19 asthmatic patients and HRV could be related with a higher severity of COVID-19.

show abstract

“… 1 , 2 As a result, patients’ experiences and expectations around healthcare are increasingly being investigated. 3 - 5 …”

Section: Introductionmentioning

confidence: 99%

Perspectives of the community in the developing countries toward telemedicine and pharmaceutical care during the COVID-19 pandemic

Alsayed¹,

Halloush²,

Hasoun³

et al. 2022

PHARMPRACT

Self Cite

View full text Add to dashboard Cite

Background: Pharmaceutical care (PC) services have expanded in recent years, resulting in improved patient outcomes. However, such PC services are currently available for free in the majority of Arabic countries. During the coronavirus disease (COVID-19) pandemic, telemedicine is especially beneficial since it allows for continuity of care while allowing for social distancing and minimizing the risk of infection. Objective: To assess the community’s attitude, opinion, and willingness to pay for telemedicine and PC services during COVID-19 pandemic, as well as to create a website provision for telemedicine and PC services. Methods: This cross-sectional study was conducted, over five months (December 2020– April 2021), among the general population in Arabic countries, excluding pharmacists, physicians, and pharmacy students. Results: A total of 1717 participants were involved, most of them were from Jordan (52.2%) and Iraq (24.8%). Sixty two percent of participants seek pharmacists’ advice whenever they have any medication changes and 45.1% of the participants agreed with the idea of paying pharmacists to decrease medication errors. Interestingly, 89.5% of participants encouraged the idea of creating a website that provides a PC, and 35.5% of them would pay for it. The failure to document the medical information of the patients had most applicants’ agreement as a reason of medical errors (M=4.17/5, SD=0.787). More than three-quarters of participants agreed that creating a database containing the patients’ medical information will reduce medical errors. Conclusion: From a patients’ perspective, this study suggests a large patient need for expanding PC services in Arabic countries and introduces a direct estimate of the monetary value for the PC services to contribute to higher savings. The majority of participants supported the idea of creating a website provision of telemedicine and PC services, and a considerable proportion of them agreed to pay for it.

show abstract

Patterns of antibiotic use, knowledge, and perceptions among different population categories: A comprehensive study based in Arabic countries

Cited by 18 publications

References 60 publications

Using laboratory parameters as predictors for the severity and mortality of COVID-19 in hospitalized patients

Using laboratory parameters as predictors for the severity and mortality of COVID-19 in hospitalized patients

Investigating the human rhinovirus co-infection in patients with asthma exacerbations and COVID-19

Perspectives of the community in the developing countries toward telemedicine and pharmaceutical care during the COVID-19 pandemic

Contact Info

Product

Resources

About